Evidence map›Paper›PMID 41430468›Full record

ArticleJournal of cancer research and clinical oncology2025

Neoadjuvant SBRT and intraoperative electron radiotherapy in pancreatic cancer resection.

Gianella Cornejo, Alon Pikarsky, Ayala Hubert, Marc Wygoda, Antoni Skripai, Aron Popovtzer, Jon Feldman, Yair Hillman, Liat Appelbaum, Mark Temper and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gianella CornejoDepartment of Surgery, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Alon PikarskyDepartment of Surgery, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Ayala HubertDepartment of Medical Oncology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Marc WygodaDepartment of Radiation Oncology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Antoni SkripaiDepartment of Radiation Oncology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Aron PopovtzerDepartment of Radiation Oncology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Jon FeldmanDepartment of Radiation Oncology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Yair HillmanDepartment of Radiation Oncology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Liat AppelbaumDepartment of Radiology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Mark TemperDepartment of Medical Oncology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Abed KhalailehDepartment of Surgery, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Ashraf ImamDepartment of Surgery, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Gideon Zamir *Department of Surgery, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Philip Blumenfeld *Department of Radiation Oncology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel. philipb@hadassah.org.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesPancreatic cancer surgery frequently results in positive margins and local recurrence despite multimodal treatment. This study evaluated whether combining neoadjuvant stereotactic body radiotherapy (SBRT) with intraoperative electron radiotherapy (IOeRT) during resection could improve local control and surgical outcomes.

methodsA retrospective analysis was performed on 15 patients with resectable or borderline resectable pancreatic adenocarcinoma treated between 2021 and 2023. All patients received image-guided, motion-managed SBRT (35-40 Gy/5 fractions to PTV_high; 25 Gy/5 fractions to PTV_low) followed by surgical resection and IOeRT (median 10 Gy; 12 Gy when margins were at risk). Toxicities were graded by CTCAE v5.0 and postoperative complications by Clavien-Dindo criteria. Follow-up included imaging and CA 19-9 every 3 months. Survival was estimated using Kaplan-Meier analysis.

resultsMean patient age was 66 years; 60% had tumors in the pancreatic body and 40% in the head. Two-thirds were borderline resectable and received neoadjuvant chemotherapy. Margin-negative resection was achieved in 86.7%, including two complete pathologic responses in BRCA2-mutated tumors. Median overall and progression-free survival were 30 and 16 months, respectively. One patient (6.7%) developed isolated local recurrence, while distant metastases occurred in over half. Toxicities were mainly grade 1-2 fatigue, nausea, or pain; surgical complications were grade 1-2 in 53%, grade 3 in 7%, and grade 5 in 7%.

conclusionsNeoadjuvant SBRT with IOeRT during pancreatic cancer resection is feasible, achieves high rates of negative margins, and provides promising local control. Distant progression remains the dominant mode of failure.

Indexed as

AdenocarcinomaElectronsPancreatic NeoplasmsRadiosurgeryAgedAged, 80 and overCombined Modality TherapyFemaleHumansMaleMiddle AgedNeoadjuvant TherapyRetrospective StudiesIntraoperative electron radiotherapy (IOeRT)Pancreatic cancer resectionStereotactic body radiotherapy (SBRT)

Identifiers

PMID41430468
PMCPMC12722610

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.